Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27006295 | 0.82 | RET (0.40) | MAOBALDH1A1LMNAMAPTNPSR1 | |
| SCHEMBL27018775 | 0.81 | CYP19A1 (0.46) | MAOBALDH1A1CYP19A1MAPTCYP1A2 | |
| SCHEMBL27018784 | 0.81 | CYP19A1 (0.46) | MAOBALDH1A1CYP19A1MAPTCYP1A2 | |
| SCHEMBL27779717 | 0.81 | CYP19A1 (0.46) | MAOBALDH1A1CYP19A1MAPTCYP1A2 | |
| SCHEMBL5349568 | 0.81 | CYP19A1 (0.46) | MAOBALDH1A1CYP19A1MAPTCYP1A2 | |
| SCHEMBL17860841 | 0.80 | MAPT (0.46) | MAOBALDH1A1LMNAMAPTATM | |
| SCHEMBL11386400 | 0.79 | KDM1A (0.41) | MAOBCYP19A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11386397 | 0.79 | KDM1A (0.41) | MAOBCYP19A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11386399 | 0.79 | KDM1A (0.41) | MAOBCYP19A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11395645 | 0.79 | KDM1A (0.41) | MAOBCYP19A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | MAOB 1729/4885ALDH1A1 2121/4885LMNA 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.